Pharmaceutical industry – Page 22
-
BusinessMerck & Co and Qiagen to build UK research hubs
Almost 2000 jobs to be created at research centres in Manchester and London
-
BusinessEuropean drug regulator heads to Amsterdam
Brexit drives EMA to relocate, taking hundreds of jobs and significant expertise away from UK
-
OpinionBeyond buckets and batches
Embracing flow chemistry means leaving behind some faithful friends
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
BusinessBayer forms cancer-drug partnership with Loxo
Alliance could see Loxo net up to $1.55bn in upfront and milestone payments
-
FeatureStaying one step ahead of the game
Clare Sansom examines the need for agile drug development when tackling emerging viral disease outbreaks
-
BusinessChina clamps down on polluting factories
Thousands of factories face closure or sanctions as authorities exercise new powers to curb air and water pollution
-
BusinessChuck Norris versus gadolinium
US action star is suing 11 drug firms for $10m, claiming his wife was poisoned by gadolinium from her MRIs
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessLilly and CureVac to collaborate on mRNA cancer vaccines
Deal could see CureVac net up to $1.8 billion in upfront and milestone payments
-
BusinessGSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster
-
BusinessJudges overturn J&J talc cancer claims
Two new rulings follow trend of reversing large jury-awarded damages as firm works through thousands of cases
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry
-
BusinessDrug formula change infuriates French thyroid patients
Poor communication of changes to Merck KGaA’s levothyroxine has led to complaints of side effects
-
BusinessHurricane damage squeezes supply chains
Industry and government working to minimise impact of shortages of olefin feedstocks and medical products
-
BusinessFederal court quashes Allergan eye drop patents
Ruling negates company’s deal with Mohawk tribe to avoid patent board review
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
BusinessCall for overhaul of EU rules on GMO clinical trial
Rules designed around genetically modified plants crops are holding back new cell and gene-based medicines